Pfizer Stock Plummets to 5-Year Low Despite New Booster Push
- Pfizer stock has collapsed despite Travis Kelce marketing campaign and new COVID booster
- Stock hit 5-year low, lost $175B in value since 2021 peak
- Decline due to lack of interest in new boosters now that mandates are gone
- This year's booster tested on 8 mice, authorized despite lack of demand
- Public has lost trust after overhyped claims about effectiveness
